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Abstract
Background: Rheumatoid arthritis (RA) and its accepted animal model, murine collagen-induced
arthritis (CIA), are classic autoimmune inflammatory diseases which require proinflammatory
cytokine production for pathogenesis. We and others have previously used N, N-dimethylglycine
(DMG) and extracts from the New Zealand green-lipped mussel Perna canaliculus (Perna) as potent
immunomodulators to modify ongoing immune and/or inflammatory responses.
Methods: In our initial studies, we treated lipopolysaccahride (LPS) stimulated THP-1 monocytes
in vitro with increasing concentrations of Perna extract or DMG. Additionally, we treated rat
peripheral blood neutrophils with increasing concentrations of Perna extract and measured
superoxide burst. In subsequent in vivo experiments, CIA was induced by administration of type II
collagen; rats were prophylactically treated with either Perna or DMG, and then followed for
disease severity. Finally, to test whether Perna and/or DMG could block or inhibit an ongoing
pathologic disease process, we induced CIA in mice and treated them therapeutically with either
of the two immunomodulators.
Results: Following LPS stimulation of THP-1 monocytes, we observed dose-dependent reductions
in TNF-α and IL-12p40 production in Perna treated cultures. DMG treatment, however, showed
significant increases in both of these cytokines in the range of 0.001–1 µM. We also demonstrate
that in vitro neutrophil superoxide burst activity is dose-dependently reduced in the presence of
Perna. Significant reductions in disease incidence, onset, and severity of CIA in rats were noted
following prophylactic treatment with either of the two immunomodulators. More importantly,
amelioration of mouse CIA was observed following therapeutic administration of Perna. In
contrast, DMG appeared to have little effect in mice and may act in a species-specific manner.
Conclusion: These data suggest that Perna, and perhaps DMG, may be useful supplements to the
treatment of RA in humans.
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Background
Immunomodulation is the process of modifying an
immune response in a positive or negative manner by
administration of a drug or compound. Many proteins,
amino acids, and natural compounds have shown a sig-
nificant ability to regulate immune responses, including
interferon-γ (IFN-γ) [1-4], steroids [5-7], DMG [8-11] and
extracts from the New Zealand green-lipped mussel, Perna
[12,13]. Previous work in our laboratory demonstrated
that natural compounds, including Perna [13,14] and
DMG [10], exhibit both humoral and cellular immu-
nomodulating effects.
Perna, a New Zealand green-lipped mussel preparation,
has demonstrated strong anti-inflammatory properties
and was shown to be as efficient as non-steroidal anti-
inflammatory drugs (NSAIDs) at reducing inflammation
in rats with carrageenan-induced footpad edema [12].
Furthermore, following Perna treatment inhibition of
proinflammatory prostaglandins was described in preg-
nant rats [15]. A lipid-rich extract of Perna was shown to
prevent the development of adjuvant-induced polyarthri-
tis and collagen-induced auto-allergic arthritis in rats [16].
This therapeutic effect was associated with the inhibition
of prostaglandins and leukotriene B4 biosynthesis. More-
over, Perna contains the histamine blocker lysolecithin
that also likely contributes to its anti-inflammatory prop-
erties [17].
DMG, an intermediate in the degradation of choline, also
appears to be an effective immunomodulator. As a signif-
icant part of a calcium pangamate preparation, DMG was
reported to help reverse immunosuppression after irradi-
ation in guinea pigs [8]. Following antigenic challenge,
DMG alone enhanced antibody levels and lymphocyte
proliferation in both humans [9] and rabbits [10]. When
DMG was administered in vitro to hybridoma cells, anti-
body output significantly increased (unpublished data).
Interestingly, DMG was shown to reduce ulcer number,
size and index after gastric ulcer induction by either its free
radical scavenging activity and/or cytoprotection of the
gastric lining [18].
CIA is a well-established animal model of human RA [19].
Injection of native type II collagen (CII) leads to the devel-
opment of severe polyarticular arthritis in primates and
rodents. This model, which relies upon the host's own
immune system, is associated with synovitis and erosion
of both bone and cartilage leading to severe loss of joint
function. The mechanism(s) underlying the disease are
not clearly defined, but both B cells and T cells are clearly
involved in its pathogenesis [20].
In this paper, we demonstrate that in vitro treatment with
extracts derived from Perna canaliculus inhibited the pro-
duction of several proinflammatory cytokines by a mono-
cytic cell line. In addition, similarly treated neutrophils
showed deficiencies in effector function. Rats treated pro-
phylactically with either DMG or Perna showed reduced
incidence and onset of CIA. Remarkably, mice with estab-
lished CIA treated with Perna showed significantly
reduced joint inflammation and amelioration of disease.
These findings indicated that Perna, DMG or perhaps a
combination of the two might be effective therapeutic
agents in the treatment of RA.
Methods
Perna and DMG
Perna® is lyophilized Perna canaliculus powder provided by
FoodScience Corporation (Essex Junction, VT, USA). The
freeze dried green-lipped mussel powder used in these
studies is produced from the entire mussel (minus the
shell) and was supplied by Aroma New Zealand Ltd,
Christchurch, New Zealand. Perna was extracted with
0.1% Tween-20 overnight, filtered, and protein content
determined by Bradford assay as described [13]. The N, N-
Dimethylglycine (DMG) free base (mp 180–183°C) was
also provided by FoodScience Corporation. As deter-
mined by trypan blue exclusion, Tween-20 extracts of
Perna, even at 10 times the highest concentration used in
this study, did not affect viability of primary human neu-
trophils or peripheral blood mononuclear cells or any of
9 other cell lines tested, including V2E9, THP-1, L-929, U-
937, A375.S2, Jurkat E6-1, EL-4, LS174T, and human kid-
ney cells [13]. Similar studies with DMG also showed no
DMG-induced cytotoxicity at concentrations 10 times
those used in this study (data not shown).
DMG and Perna cytokine assays
Human THP-1 monocytes (American Type Tissue Collec-
tion, Manassas, VA) were differentiated into mature
monocytes in 1.2% DMSO overnight. Cells were washed
and then primed with recombinant IFN-γ (10 ng/ml) for
16 hrs and preincubated for 2 hrs with or without increas-
ing concentrations of DMG or Perna extract. Monocytes
were stimulated overnight with LPS (1 µg/ml) after which
IL-12p40 and tumor necrosis factor-α (TNF-α) levels were
determined 48 hrs later by ELISA (BioLegend, San Diego,
CA).
Neutrophil superoxide assay
Perna (1 g) was extracted in 10 ml of 30% phenol by stir-
ring for 45 min at room temperature, precipitated with
ethanol, and resuspended in water. Samples were precipi-
tated a second time with ethanol, again resuspended in
water, dialyzed against water overnight (8–12 kD dialysis
membrane tubing), frozen, and freeze-dried producing a
fine powder of Perna extract. Rat neutrophils were iso-
lated from peripheral blood and equal numbers of neu-
trophils were added to wells of a 96-well plate inBMC Complementary and Alternative Medicine 2007, 7:20 http://www.biomedcentral.com/1472-6882/7/20
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appropriate culture medium. Perna extract at 0, 100, 200,
and 400 µg/ml was added to the cultures and neutrophils
were activated with 50 ng/ml of the mitogen, phorbol 12-
myristate 13-acetate (PMA). Percent inhibition of super-
oxide generation was calculated as described [21].
Animal and treatment groups
Female Wistar rats were obtained from Charles River Lab-
oratories (Wilmington, MA). Female DBA/1J mice were
obtained from The Jackson Laboratory (Bar Harbor, ME).
Rats were separated into 4 treatment groups: control;
DMG (100 mg/kg/day); Perna (100 mg/kg/day); or DMG
plus Perna (100 mg/kg/day DMG plus 100 mg/kg/day
Perna). Rats were injected with type II collagen and fol-
lowed for incidence and onset of CIA, as well as degree of
paw inflammation. In contrast, following induction of
CIA, mice were randomly assigned to one of 3 therapeutic
treatment groups: control-, Perna-, or DMG-treated. Perna
was administered daily by either preformed pellets of
rodent chow/Perna mix at a 1:1 ratio or by grinding chow
pellets and mixing it with Perna powder at the same ratio.
For the mice, DMG was either dissolved in drinking water
at 1.7 mg/ml or for the rats, DMG was injected daily intra-
peritoneal (i.p.) at 100 mg/kg in saline. Mice drank
~0.94–1.43 ml of the DMG-water solution per day that
provided ~2–3 mg of DMG per day (100–150 mg/kg/
day). In addition, 3 control groups (10 mice/group) were
treated with Perna, DMG or control chow/water at identi-
cal concentrations except arthritis was not induced. No
toxic side effects were noted in any of these control
groups. If the compounds were administered orally, food
and water consumption from the animals was carefully
monitored to assure each animal was receiving the pre-
scribed daily dosage of Perna or DMG. The experimental
protocol was carried out under the supervision of the
Clemson University Institutional Animal Research Com-
mittee.
Induction of collagen-induced arthritis
Type II collagen from chicken sternal cartilage (Sigma
Chemical Co., St. Louis, MO) was dissolved in 0.01 N ace-
tic acid (2 mg/ml) by stirring overnight at 4°C. The colla-
gen solution was emulsified in complete Freund's
adjuvant (CFA) (Sigma) at a ratio of 6:4. In rats, collagen
was administered intradermal (i.d.) into the left hind
foot-pad with a booster injection into the tail one week
later, and in mice 100 µg of type II collagen was injected
i.d. into the base of the tail. Booster CII injections with
incomplete Freund's adjuvant (Sigma) were administered
at the base of the tail into mice that had not yet exhibited
clinical signs of arthritis on days 14, 30 and 73. Rats
showed 58% incidence with time of onset at 16–24 days
following immunization. Mice had an 83% incidence
with time of onset ~28–32 days following immunization.
Assessment of arthritic severity
Animals were examined twice daily for signs of footpad
erythema and joint swelling/locking. Joint locking was
monitored in rats at which time joints were measured
using mm calipers. Mouse arthritis was graded on a 4-
point scale of 0–3: 0, no pathology; 1, swelling in one
limb; 2, moderate swelling in multiple limbs with joint
locking; and 3, pronounced swelling in all four limbs with
joint locking.
Serology
Sera were collected from rats on day 7 and periodically
after until development of CIA, which typically occurred
between days 16 and 22. Anti-collagen antibody levels
were determined by ELISA as previously described [22].
Briefly, plates were coated with collagen (5 µg/mL) over-
night at 4°C. Plates were then blocked with ovalbumin
and diluted serum samples (1:10,000) were incubated for
2 hrs at room temperature (RT). IgG and IgM titers were
revealed with appropriate anti-rat horseradish peroxidase
conjugates (Sigma). Plates were read at 495 nm on a
Dynatech ELISA plate reader.
Interleukin-2 (IL-2) bioassay
IL-2 activity was determined by the proliferative response
of the IL-2-dependent-cell line CTLL-2 (ATCC, Manassas,
VA) to serum IL-2. 50 µl of sera from treated or untreated
rats were added to CTLL-2 cells cultured at 2 × 105 cells/ml
on 96-well plates at 37°C in assay medium not containing
IL-2. After 24-hr incubation, [3H]-thymidine (2 Ci/mmol,
ICN Biomedical Inc., Irvine, CA) was added to each well
and plates were incubated for an additional 4–6 h. CTLL-
2 cells were harvested onto glass-fiber filters and incorpo-
rated radioactivity was counted in a beta-scintillation
counter. An IL-2 standard was run with each assay to con-
vert the counts per minute (CPMs) to IL-2 units.
Immunoassay for rheumatoid factors
96-well microtiter plates were coated with rat IgG (5 µg/
ml). Plates were blocked, washed, and 100 µl of treated or
untreated rat serum (diluted 1:100) were added to the
wells in triplicate. Following overnight incubation at 4°C,
wells were washed and 100 µl of F(ab)2 goat anti-rat IgG
peroxidase conjugate or F(ab)2 goat anti-rat IgM (µ-chain
specific) peroxidase conjugate, (Jackson ImmunoRe-
search Laboratories, West Grove, PA) was added, and
incubation was continued for 4 hrs at room temperature
(RT). Plates were again washed and 100 µl of substrate
solution containing ortho-phenylenediamine (Sigma)
was added. After ~20 minutes, 50 µl of H2SO4 stop solu-
tion was added to each well and rheumatoid factor levels
were determined by reading absorbance at 492 nm, (Tit-
ertek Mutiskan MCC/340, Labsystems, Finland).BMC Complementary and Alternative Medicine 2007, 7:20 http://www.biomedcentral.com/1472-6882/7/20
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Flow cytometry
Splenocytes were surface-stained with fluorescent conju-
gated antibodies to CD4, CD8 or CD45RA/B220 (BD
PharMingen, San Diego, CA). All samples were analyzed
on an EPICS 751-flow cytometer (Coulter, FL) with a Cic-
ero acquisition module and Cyclops analysis software
(Cytomation, CA).
Statistical methods
Student's unpaired t-tests were used to compare group
mean values where appropriate. CIA disease severity
scores are depicted as the average of the treatment group
per day over the treatment period and were analyzed
using the Kruskal-Wallis test for significance. Percent data
were analyzed using ANOVA for unequal subclasses (SAS
Institute, Inc.). Results are expressed as mean ± SEM. P ≤
0.05 was considered significant.
Results
Perna decreased while DMG increased TNF-α and IL-
12p40 production from THP-1 cells
Perna and DMG have been previously reported to affect
immune responses by either augmenting the response, as
in the case of DMG, or suppressing the response, as in the
case of Perna. To address this issue we used a monocytic
cell line that produces IL-12p40 and TNF-α following LPS
stimulation. We cultured the monocytes with 0–100 µM
DMG for 48 hrs and following LPS stimulation, a signifi-
cant increase in the production of both IL-12p40 and
TNF-α at concentrations of 0.001–1 µM was observed
(Figure 1). Interestingly, concentrations below 0.1 pg/ml
as in the case of TNF-α and above 1 µM as in the case of
IL-12p40 had no effect. These results are consistent with
our earlier studies showing a specific range at which DMG
is active, but above or below that concentration DMG
appears ineffective (unpublished data). In contrast, treat-
ment of the monocytes with a Tween-20 Perna extract
resulted in a dose-dependent reduction in the production
of these same cytokines, particularly at concentrations
greater than 0.1 mg/ml (Figure 2).
Neutrophil superoxide production is reduced in the 
presence of Perna
To further detail the anti-inflammatory properties of
Perna, a phenol Perna extract was generated as described
above and rat neutrophils were treated at 0–400 µg/ml
prior to PMA stimulation. In the presence of PMA, neu-
trophils normally undergo burst activity and secrete
superoxides, which can be detected in the culture medium
by the tetrazolium salt, WST-1 [21]. Indeed, Perna showed
a dose-dependent inhibition of superoxide production
with the highest concentration showing only 27.4% of the
activity of the controls, which were set at 100% activity
(Figure 3).
Prophylactic treatment with Perna and DMG reduced CIA 
development in rats
Taking the in vitro results into account, we next tested
whether Perna or DMG had beneficial effects in an in vivo
model of inflammation. Rats were immunized with type
II collagen emulsified in CFA on day 0 and treated with
Perna (100 mg/kg/day), DMG (100 mg/kg/day), a Perna-
DMG combination (each at 100 mg/kg/day) or control
rodent chow (Table 1). In the Perna treated group, 3/18
(~17%) rats developed arthritic joints with an average
paw size of 14.2 mm. DMG treated animals also had a sig-
nificant reduction in arthritic severity with 8/27 (~30%)
of rats showing acute inflammation with an average paw
size of 17.2 mm. The combination of Perna and DMG
showed beneficial effects with 2/9 (~22%) rats showing
arthritic joints with an average paw size of 19 mm. In con-
trast, 14/24 (~58%) control treated animals showed
severe joint inflammation with an average paw size of
19.5 mm. Individually, both Perna and DMG significantly
DMG promotes IL-12p40 and TNF-α production by mono- cytes Figure 1
DMG promotes IL-12p40 and TNF-α production by mono-
cytes. THP-1 human monocytes were primed with IFN-γ (10 
ng/ml) then stimulated with LPS (1 µg/ml) in the presence of 
increasing concentrations of DMG. TNF-α (panel A) and IL-
12p40 (panel B) concentrations were determined by ELISA. * 
indicates a p-value < 0.05.
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reduced paw swelling; however, the combination did not
reduce swelling albeit it did reduce the incidence of CIA.
Additionally, the combination of Perna and DMG or
DMG alone delayed CIA induction by almost 2 days as
compared to the Perna-treated and controls groups.
Perna and DMG reduced anti-collagen IgM antibodies in 
rats
Antibody responses to type II collagen were measured by
ELISA on day 16 from Perna, DMG, Perna-DMG and con-
trol treated rats. There was a significant difference in IgM
titers between Perna treated (0.5 ± 0.15 O.D. units), DMG
treated (0.4 ± 0.15 O.D. units), Perna-DMG treated (0.6 ±
0.23 O.D. units) and control (0.89 ± 0.37 O.D. units) ani-
mals to type II collagen; however, no difference was noted
in IgG subclass titers for any of the groups (Figure 4).
Additionally, IL-2 serum levels and IgM rheumatoid fac-
tors were also determined from the treatment groups with
no differences observed (data not shown).
Therapeutic administration of Perna ameliorated ongoing 
CIA in mice
Our first experiments demonstrated the prophylactic
effects of Perna and DMG on rat CIA. In a follow-up exper-
iment, we analyzed the possible therapeutic effects of
these compounds in a mouse model of CIA. In these stud-
ies, mice were first immunized with type II collagen and
followed for induction of arthritis. As mice developed dis-
ease (score ≥ 1), they were randomized into three treat-
ment groups, Perna alone (n = 12), DMG alone (n = 12)
and untreated controls (n = 15).
Mice were scored (0–3) twice daily for 107 days. One
week prior to treatment initiation, the three groups were
graded to ascertain an initial group average disease sever-
ity score. All mouse groups, on day 10 after commence-
ment of treatment, averaged a score of ~2 (Table 2). By
day 81, a 95% confidence interval test showed a signifi-
cant difference between the severity scores of the Perna
versus the DMG or control groups and the Kruskal-Wallis
test showed a similar significant difference over the course
of the entire experiment (Figure 5). Sixty-one percent of
control mice fed a standard rodent chow diet ended the
study with an average score of 3 (most severe) indicating
multiple locked and highly inflamed joints. Similarly,
59% of mice that consumed DMG in their water ended
the study with an average severity score of 3. In contrast,
only 20% of mice fed Perna mixed with standard mouse
chow ended the study with a disease score of 3. The con-
trol group spiked at day 92 with an average score of 2.85
Perna extract inhibits superoxide production and burst activ- ity by neutrophils Figure 3
Perna extract inhibits superoxide production and burst activ-
ity by neutrophils. Rat neutrophils were isolated from 
peripheral blood and stimulated with PMA (50 ng/ml) in the 
presence of increasing concentrations of Perna extract. Per-
cent inhibition was calculated by comparing Perna extracts 
with untreated cells. * indicates a p-value < 0.05.
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Perna extract inhibits IL-12p40 and TNF-α production by  monocytes Figure 2
Perna extract inhibits IL-12p40 and TNF-α production by 
monocytes. THP-1 human monocytes were primed with 
IFN-γ (10 ng/ml) then stimulated with LPS (1 µg/ml) in the 
presence of increasing concentrations of Perna extract. TNF-
α (panel A) and IL-12p40 (panel B) concentrations were 
determined by ELISA. * indicates a p-value < 0.05.
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indicating that the majority of the mice in this group had
multiple joint involvement. These mice exhibited severe
swelling and edema and usually all four limbs were signif-
icantly inflamed. By the end of the study, the control
group had dropped slightly with an average severity score
of 2.63. The DMG group was similar to the control group
except they spiked much earlier (day 52), with an average
score of 2.9 and ended the study with an average score of
2.71. In contrast, the Perna treated group peaked at day 40
with an average score of 2.4. However, by day 107, the
average group severity score of the Perna group was mark-
edly reduced to 1.42. In the Perna fed group, a reversal of
inflammation occurred by the end of the study with one
animal completely free of disease and eight others show-
ing only mild limb swelling. Additionally, control mice
that were simultaneously fed the same experimental diets
as the CIA groups, but were not immunized with type II
collagen did not show any overt signs of toxicity or paw
inflammation for up to 172 days.
DMG and Perna did not alter T and B cell ratios
On day 107, splenocytes from all three mouse treatment
groups were stained with anti-CD4, CD8 and CD45/B220
for flow cytometric analysis. Following arthritic induc-
tion, CD4 and CD8 T and B cell frequencies were mostly
unaffected by either of the two treatments (Table 3).
Although some treatment group data were statistically dif-
ferent from the control group, the biological relevance of
these very small changes is unclear. Additionally, absolute
counts of total splenic T and B cells were unchanged
among all groups (data not shown).
Discussion
In this paper, we examined the prophylactic and therapeu-
tic effects of the immunomodulators Perna and DMG in
two separate animal models of inflammation, rat and
mouse CIA. We observed differing results, in particular
Table 2: Effect of Perna and DMG on established CIA in mice
Group N Treatment 
(mg/kg/day)
Initial Arthritic 
Score
Final Arthritic 
Score
Control 15 N/A 2.0 ± 0.13 2.63 ± 0.55
Perna 12 100 2.2 ± 0.2 1.42 ± 0.24 a
DMG 12 100 2.1 ± 0.17 2.71 ± 0.41
CIA was induced and mice were treated as indicated. Initial and final 
arthritic scores were determined by averaging individual daily scores 
within a group (mean ± s.e.m.). The arthritic score was graded from 
0–3: 0, no pathology; 1, swelling in one limb; 2, moderate swelling in 
multiple limbs with joint locking; and 3, pronounced swelling in all four 
limbs with joint locking. To determine statistical significance, 
treatment groups were compared to the control group and analyzed 
by the Kruskal-Wallis test. a indicates p < 0.05 compared to controls.
Table 1: Effect of Perna and DMG on CIA in rats
Group Treatment (mg/kg/day) Incidence (%) Day of CIA Onset (day) Paw Size (mm)
Control N/A 58.3 (14/24) 18.7 ± 1.6 19.5 ± 3.8
Perna 100 16.6 (3/18)a 19.5 ± 1.6 14.2 ± 0.7a
DMG 100 29.6 (8/27)a 20.4 ± 1.7 17.2 ± 3.0
Perna + DMG 100 + 100 22.2 (2/9)a 20.5 ± 0.5 19.0 ± 1.4
Rats were treated as indicated and incidence, onset and average paw size were determined. Numbers are given as mean ± s.e.m. a indicates p < 0.05 
compared to controls.
Perna and DMG reduce IgM (panel A), but not IgG (panel B)  anti-type II collagen antibody levels Figure 4
Perna and DMG reduce IgM (panel A), but not IgG (panel B) 
anti-type II collagen antibody levels. Rats were untreated, 
treated with Perna, DMG, or the combination of the two. 
Anti-collagen levels were analyzed from serum by ELISA. * 
indicates a p-value < 0.05.
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with regards to the effects of DMG, depending upon
which animal model was used. For example, in rats DMG
showed a protective effect; however, in mice DMG
appeared ineffective as a therapeutic agent. Perna, on the
other hand, was shown to be very beneficial in both ani-
mal models. The beneficial effects of Perna were associ-
ated with reductions in anti-collagen antibody levels, pro-
inflammatory cytokine production, superoxide release,
and amelioration of established CIA.
The mechanism(s) by which DMG acts in these animals is
still unknown and may be, as suggested here, species spe-
cific. In support of this idea, humans [9] and rabbits [10]
both show increased humoral and cellular immune
responses following DMG administration. In contrast,
however, it was reported that virus neutralizing antibody
levels to an inactivated feline virus vaccine showed
reduced levels of anti-viral antibodies, as well as inter-
feron activity following DMG treatment [11]. In contrast,
we found that DMG acted negatively on the immune
response in rats, thus decreasing the severity and inci-
dence of CIA. But, in mice, DMG had no appreciable effect
in the arthritic model. Therefore, similar to the cat study,
DMG may cause an overall reduction in anti-collagen
antibodies resulting in reduced CIA severity and incidence
as is the case with rats. It has previously been suggested
that low-affinity antibodies to collagen are necessary for
CIA pathogenesis in rats [23], thus DMG may inhibit pro-
duction of these pathologic antibodies. In total, these data
suggest species specific responses to DMG, and depending
upon the desired clinical outcome, one has to carefully
assess how DMG may interact with the immune system of
a given species. Alternatively, the species differences could
be related to the fact that Wistar rats are outbred while
DBAJ/1 mice are inbred. Of note, humans with RA and
osteoarthritis treated with a combination of DMG and
Perna have reported beneficial effects (unpublished data).
These data, although anecdotal, suggest that DMG either
acts synergistically with Perna or the anti-inflammatory
effects of Perna mask the unknown stimulatory effects of
DMG. Due to the apparent species specific effects of
DMG, further studies in humans addressing this matter
appear warranted.
It was previously noted in New Zealand that native Maori
tribes who lived in close proximity to the sea had a greatly
reduced incidence of arthritis in comparison to other
Maori that lived in the interior area of the country [24].
Diets were found to be similar except that coastal tribes
consumed much higher quantities of the green-lipped
mussel Perna canaliculus. Here, we report a consistent sig-
nificant reduction in arthritic inflammation when rats or
mice were treated prophylactically or therapeutically with
Perna. Our results are supported by several other groups
detailing reduced inflammation in Perna treated arthritic
dogs [25,26], arthritic humans [27-29], and carrageenan-
induced rat paw edema [12,30]. This anti-inflammatory
effect has been attributed to several factors, one of which
is a reduction in the biosynthesis of the proinflammatory
prostaglandins. It was reported that green-lipped mussel
powder increased the gestation period of rats, suggesting
that Perna contains active inhibitors of prostaglandin pro-
duction [15]. Work with the lipid fraction of Perna has
also been associated with high levels of anti-inflammatory
activity due to the presence of omega-3 polyunsaturated
fatty acids [16], which block arachidonic metabolism by
the cyclooxygenase (COX) and lipoxygenase pathways.
Indeed, our laboratory recently reported that several
extracts of Perna could potently block the activity of both
the COX-1 and COX-2 enzymes in a dose-dependent
Table 3: Effect of Perna and DMG on T and B cell populations 
following CIA induction
Groups Control (%) Perna (%) DMG (%)
CD4+ 24.6 ± 1.1 27.5 ± 1.3a 22.1 ± 1.3
CD8+ 10.4 ± 0.6 10.3 ± 0.8 8.0 ± 0.8a
CD45R/B220 47.8 ± 1.1 51.0 ± 1.3a 54.0 ± 1.3a
Following CIA induction, mice were treated as indicated and the 
percentage of splenic T and B cells was determined. Numbers are 
given as percentages (mean ± s.e.m.). a indicates p < 0.05 compared to 
controls.
Perna treatment ameliorated established CIA Figure 5
Perna treatment ameliorated established CIA. After CIA 
induction, mice were randomly assigned to Perna (red dotted 
line), DMG (black dashed line) or control (blue solid line) 
groups and scored twice daily for 107 days. Scoring was 
based on the following criteria: 0, no pathology; 1, swelling in 
one limb; 2, moderate swelling in multiple limbs with joint 
locking; and 3, pronounced swelling in all four limbs with 
joint locking.
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manner [13]. This blockade in the COX pathways was also
associated with marked reductions in several proinflam-
matory cytokines such as IL-1, IL-2, IL-6 and TNF-α. We
confirm here a dose-dependent reduction in TNF-α pro-
duction from stimulated monocytes, as well as a reduc-
tion in neutrophil burst activity. The disease-promoting
role of TNF-α in RA has been well established [31,32] as it
appears to directly regulate the proinflammatory network,
and agents which reduce levels of systemic TNF-α are
already in the clinic [33,34] or are actively being investi-
gated. TNF-α and both types of the TNF-α R are easily
detectable in synovial fluid as either protein [35-37] or
mRNA [38,39] and numerous reports have demonstrated
worsening of CIA following treatment with TNF-α
[40,41], whereas administration of anti-TNF-α antibodies
[42-44] or IgG-TNF-receptor fusion proteins [45,46]
blocked development and ameliorated disease.
It has also been suggested that green-lipped mussel pow-
der is non-gastrotoxic [16,18], and preferentially blocks
the proinflammatory COX-2 enzyme over the more phys-
iologically important COX-1 enzyme, thus perhaps mak-
ing Perna safer than NSAIDs. On the other hand, extensive
disruption of the ratio of COX-1 to COX-2 activity may be
involved with cardiovascular abnormalities [47]. Our
data, however, indicated that both enzymes systems were
inhibited, albeit COX-2 activity was more effectively
reduced than COX-1 (13).
We also previously (13, 14) developed bioassays to deter-
mine whether Perna modulated either or both antibody
and inflammatory cytokine production. Extracts of Perna
canaliculus derived from Tween-20, acid, or ethanol treat-
ment were shown to significantly decrease the production
of TNF-α, IL-1, IL-2, and IL-6 as well as hybridoma anti-
body production. Cytokine decreases ranged from ~48%
in the case of TNF-α to ~10% in the case of IL-1. These
inhibitory effects, including the smaller percentage
changes noted with IL-1, were abolished following treat-
ment of the various extracts with several proteolytic
enzymes. Miller et al., also found that Perna harbored an
anti-inflammatory component susceptible to proteolysis
and both ethanol and lipid extracts of Perna were no
longer effective, after protease treatment, in inhibiting
inflammation associated with injection of carrageenan
and thought to be mediated by inflammatory cytokines,
especially TNF-α [12]. These decreases in the levels of
inflammatory cytokines demonstrated in the bioassays
support the present work and may help explain the
delayed onset of arthritis in CIA rats or even the reversal
of inflammation observed in the CIA Perna-treated mice.
Conclusion
Overall, we demonstrated significant immunomodula-
tory effects of DMG and in particular Perna. As many
inflammatory and autoimmune diseases, such as RA,
Crohn's disease, psoriasis, ankylosing spondylitis and per-
haps asthma, require abnormally high levels of TNF-α for
pathogenesis, interference in its production by nontoxic
natural compounds such as Perna and DMG may likely
prove beneficial.
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